Orano Med

In a collaboration that spans state-owned nuclear expertise and biotech innovation, Orano Med and Molecular Partners have joined forces to develop a novel class of cancer drugs that combines highly pr

In late October 2024, the first patient in a trial of Ariceum’s radioligand therapy (RLT) for glioblastoma, an aggressive brain cancer, showed 50% tumor shrinkage after just four to six weeks of tre

Following its surprise swerve into the radiopharmaceutical space last month, Sanofi has doubled down by forming a joint venture with alpha therapy specialist Orano Med. The big pharma is to invest €30

The radiopharmaceutical space saw a couple of huge deals at the end of last year, and another flurry, albeit on a rather smaller scale, happened this week. On September 12, both Sanofi and ITM Isot